RU2017145692A3 - - Google Patents

Download PDF

Info

Publication number
RU2017145692A3
RU2017145692A3 RU2017145692A RU2017145692A RU2017145692A3 RU 2017145692 A3 RU2017145692 A3 RU 2017145692A3 RU 2017145692 A RU2017145692 A RU 2017145692A RU 2017145692 A RU2017145692 A RU 2017145692A RU 2017145692 A3 RU2017145692 A3 RU 2017145692A3
Authority
RU
Russia
Application number
RU2017145692A
Other languages
Russian (ru)
Other versions
RU2017145692A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017145692A publication Critical patent/RU2017145692A/ru
Publication of RU2017145692A3 publication Critical patent/RU2017145692A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • A61K8/675Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2017145692A 2015-06-10 2016-02-25 Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи RU2017145692A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562173733P 2015-06-10 2015-06-10
US62/173,733 2015-06-10
PCT/US2016/019653 WO2016200447A1 (en) 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Publications (2)

Publication Number Publication Date
RU2017145692A RU2017145692A (ru) 2019-07-10
RU2017145692A3 true RU2017145692A3 (enExample) 2019-07-31

Family

ID=57503873

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017145692A RU2017145692A (ru) 2015-06-10 2016-02-25 Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи

Country Status (13)

Country Link
US (2) US11426398B2 (enExample)
EP (1) EP3307754B1 (enExample)
JP (1) JP2018517774A (enExample)
KR (1) KR20180021784A (enExample)
CN (1) CN107849083A (enExample)
AU (2) AU2016274126A1 (enExample)
CA (1) CA2989115C (enExample)
ES (1) ES2932801T3 (enExample)
MX (2) MX389207B (enExample)
RU (1) RU2017145692A (enExample)
TW (1) TWI725033B (enExample)
WO (1) WO2016200447A1 (enExample)
ZA (1) ZA201800056B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016200447A1 (en) 2015-06-10 2016-12-15 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用
US11389468B2 (en) 2017-03-17 2022-07-19 Elysium Health, Inc. Nicotinamide riboside for use in treating or preventing liver damage
US11129843B2 (en) * 2017-04-24 2021-09-28 Elysium Health, Inc. Treating and preventing kidney damage
ES3004332T3 (en) * 2017-05-17 2025-03-12 Univ De Valencia Estudi General Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
WO2019023471A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
US20200330497A1 (en) * 2017-10-19 2020-10-22 Elysium Health, Inc. Prevention and treatment of tdp-43 associated diseases
WO2019108875A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating glaucoma
WO2019108873A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
EP3930728A1 (en) * 2019-02-26 2022-01-05 Universitat de Valencia - Estudi General Methods and compositions for treating motor neuron diseases
WO2020190703A1 (en) * 2019-03-21 2020-09-24 Elysium Health, Inc. Methods for wound treatment
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
CN113712193A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 修复皮肤系统的组合物制备方法及其用途
US20230270770A1 (en) * 2020-07-30 2023-08-31 Moises HERNANDEZ-VAZQUEZ Nutritional supplements for repairing muscle and defending against deterioration from human aging
CA3227520A1 (en) * 2021-08-02 2023-02-09 Laurent GARCON Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK1957086T3 (en) * 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
CN103547256A (zh) 2011-03-23 2014-01-29 加利福尼亚大学校务委员会 炎性和传染性皮肤病的治疗
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CN105873937A (zh) 2013-10-30 2016-08-17 可劳迈戴斯有限公司 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
BR112016028672A2 (pt) * 2014-06-06 2017-08-22 Glaxosmithkline Ip No 2 Ltd análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo
MX390185B (es) * 2015-03-16 2025-03-20 Chromadex Inc Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
WO2016200447A1 (en) 2015-06-10 2016-12-15 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Also Published As

Publication number Publication date
TWI725033B (zh) 2021-04-21
US12109206B2 (en) 2024-10-08
WO2016200447A1 (en) 2016-12-15
EP3307754B1 (en) 2022-09-14
CN107849083A (zh) 2018-03-27
MX2017016024A (es) 2018-08-15
EP3307754A1 (en) 2018-04-18
MX389207B (es) 2025-03-20
JP2018517774A (ja) 2018-07-05
CA2989115C (en) 2024-01-02
US20180353497A1 (en) 2018-12-13
AU2020286208B2 (en) 2022-11-10
AU2020286208A1 (en) 2021-01-07
RU2017145692A (ru) 2019-07-10
AU2016274126A1 (en) 2018-01-18
ZA201800056B (en) 2023-10-25
KR20180021784A (ko) 2018-03-05
EP3307754A4 (en) 2019-03-27
CA2989115A1 (en) 2016-12-15
US11426398B2 (en) 2022-08-30
MX2021012600A (es) 2021-11-12
ES2932801T3 (es) 2023-01-26
TW201713322A (zh) 2017-04-16
US20220362233A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
RU2017145692A3 (enExample)
BR112017026097A2 (enExample)
BR0002874B1 (enExample)
BR0003166B1 (enExample)
BR0008719B1 (enExample)
BR0008604B1 (enExample)
BR0008158B1 (enExample)
BR0008132B1 (enExample)
BR0007834B1 (enExample)
BR0007747B1 (enExample)
BR0007688B1 (enExample)
BR0007672B1 (enExample)
BR0009717B1 (enExample)
BR0007487B1 (enExample)
BR0007468B1 (enExample)
BR0006866B1 (enExample)
BR0006854B1 (enExample)
BR0006634B1 (enExample)
BR0005085B1 (enExample)
BR0005041B1 (enExample)
BR0004687B1 (enExample)
BR0003928B1 (enExample)
BR0003751B1 (enExample)
CN303072204S (enExample)
CN303071958S (enExample)